Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer
Authors:
- Yoshifumi MoritaYMYoshifumi Morita
- Takanori SakaguchiTSTakanori Sakaguchi
- Ryo KitajimaRKRyo Kitajima
- Satoru FuruhashiSFSatoru Furuhashi
- Ryota KiuchiRKRyota Kiuchi
- Makoto TakedaMTMakoto Takeda
- Takanori HiraideTHTakanori Hiraide
- Yasushi ShibasakiYSYasushi Shibasaki
- Hirotoshi KikuchiHKHirotoshi Kikuchi
- Hiroyuki KonnoHKHiroyuki Konno
- Hiroya TakeuchiHTHiroya Takeuchi
Open Access
- 2 May 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 416
Abstract
Postoperative chemotherapy is beneficial for many pancreatic cancer patients. However, some patients require dose reduction or the discontinuation of adjuvant chemotherapy because of adverse treatment-related effects. In this study, we aimed to evaluate two main outcomes. First, we evaluated the clinicopathological factors affecting patient disease-free survival (DFS) and overall survival (OS) following upfront surgery. Second, we evaluated the factors that influence the continuity of adjuvant chemotherapy. Fifty-four patients with resected pancreatic cancer were enrolled. First, we evaluated the clinicopathological factors affecting postoperative survival using the Kaplan-Meier method and Cox regression method. Next, factors affecting the continuity of adjuvant chemotherapy were analyzed using multiple logistic regression analysis. Univariate and multivariate analyses revealed that positive LN metastasis (HR (95% CI) 6.329 (2.381–16.95); p < 0.001) and relative dose intensity (RDI) < 80% for adjuvant chemotherapy (HR (95% CI) 5.154 (1.761–15.15); p = 0.003) were independent predictive factors for DFS. Regarding OS, extended dissection of the nerve plexus around the superior mesenteric artery (SMA) (HR (95% CI) 4.504 (1.721–11.76); p = 0.002), positive microscopic surgical margin (HR (95% CI) 5.565 (1.724–17.96); p = 0.004), and adjuvant chemotherapy of RDI < 80% (HR (95% CI) 3.534 (1.135–2.667); p = 0.029) were also independent predictive factors. Moreover, the level of RDI significantly correlated with DFS and OS. Multiple logistic regression analysis revealed that low RDI was significantly associated with postoperative body weight loss (BWL) ≥ 10%. The following factors were significantly associated with poor survival: extended dissection of the nerve plexus around the SMA, lymph node metastasis, residual tumor, and RDI of the adjuvant chemotherapy. Patient’s prognosis with adjuvant chemotherapy of RDI < 80% was worse. BWL ≥10% was the most important factor affecting the continuity of adjuvant chemotherapy. Perioperative nutritional intervention is necessary for patients who receive adjuvant chemotherapy for advanced pancreatic cancer.Keywords
This publication has 26 references indexed in Scilit:
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric CancerAnnals of Surgical Oncology, 2012
- Pancreatic Cancer: Epidemiology and Risk FactorsDigestive Diseases, 2010
- Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic CancerAnnals of Surgical Oncology, 2010
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancerSurgery, 2007
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinomaSurgery, 2005
- Prognostic Factors Following Curative Resection for Pancreatic AdenocarcinomaAnnals of Surgery, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976